Pharmacodynamic test method for cough-relieving mixture

Abstract

The invention discloses a pharmacodynamic test method for a cough relieving mixture, which comprises the following steps: constructing four core pharmacodynamic test sub-models containing ammonia water to cause young mouse cough, citric acid to cause young guinea pig cough, rabbit in-vitro trachea cilia mucus movement and young mouse trachea phenol red excretion and a body model of a test result analysis sub-model; each pharmacodynamic test sub-model is provided with a plurality of groups of test arrays and test individuals; pathogen data is imported to generate a simulated disease scene, and a corresponding drug sequence is called to intervene and collect physiological index change data; and multi-dimensional pharmacodynamic parameters are evaluated through the analysis sub-model, and a dose-effect relation curve and an evaluation report are generated. According to the invention, a parallel verification system for antitussive and expectorant tests is formed, the antitussive effective dose, the expectorant effective dose and the effective dose range under the dual action of the medicine are determined through multi-model cross validation, the accuracy degree of judging the effectiveness of the medicine is greatly improved, and a reliable method support is provided for evaluating the efficacy of the cough-stopping mixture.

Description

Technical Field

[0001] This invention relates to the field of pharmacodynamic testing technology for traditional Chinese medicine compound preparations, specifically to a pharmacodynamic testing method for cough-relieving compound preparations. Background Technology

[0002] Currently, the efficacy assessment of antitussive and expectorant drugs in traditional Chinese medicine compound preparations typically relies on single experimental models or discrete data analysis. For example, in traditional methods, antitussive and expectorant tests are often conducted independently, lacking systematic correlation analysis, making it difficult to comprehensively determine the synergistic effect and dose-matching relationship of the drugs under their dual antitussive and expectorant effects. Furthermore, the exploration of the effective dose is often based on single controls or limited dose gradients, making cross-validation difficult and affecting the accuracy of drug efficacy assessment. Summary of the Invention

[0003] In view of this, the purpose of the present invention is to provide a pharmacodynamic testing method for cough-relieving compound to solve the technical problems mentioned in the prior art.

[0004] The pharmacodynamic testing method for cough-relieving compound preparations includes the following steps: According to the testing requirements, the corresponding organism data is selected to construct the organism model; the organism model is set with several drug efficacy test sub-models and test result analysis sub-models that are associated with all the drug efficacy test sub-models, and each drug efficacy test sub-model is set with at least two test arrays based on the same organism data; Pathogen data is imported into the organism model. The organism model is configured with a corresponding number of drug efficacy test sub-models according to the input category of the pathogen data. In the drug efficacy test sub-model, a corresponding number of test individuals are configured in each test array based on the number of pathogen data to be tested. At the same time, the pathogen data is distributed one-to-one to be fused with the data of multiple test individuals in each test array, so that each test individual becomes ill to load the simulated test scenario. In the simulated test scenario, the organism model is automatically triggered to retrieve the corresponding drug sequence from its built-in drug configuration database according to the input category of the pathogen data, and send it to the corresponding drug efficacy test sub-model for intervention within the set test period to obtain physiological indicator change data of each test individual after drug administration; The physiological index changes of all the test individuals after administration are sent to the test result analysis sub-model. The multi-dimensional efficacy parameters of the cough-relieving compound are evaluated according to the set analysis process. The efficacy of the drug is determined based on the multi-dimensional efficacy parameters of the cough-relieving compound. At the same time, a dose-response curve is generated and a pharmacodynamic evaluation report is output.

[0005] Optionally, the pharmacodynamic test sub-model can be any one of the following: ammonia-induced cough model in young mice, citric acid-induced cough model in young guinea pigs, rabbit isolated tracheal ciliary mucus movement model, and young mouse tracheal phenol red excretion model.

[0006] Optionally, the analysis process is set as follows: Based on the ammonia-induced cough model in young mice and / or the citrate-induced cough model in young guinea pigs, the effective dose of the antitussive compound in the antitussive test was explored. Based on the rabbit isolated tracheal ciliary mucus movement model and / or the tracheal phenol red excretion model of young mice, the efficacy and effective dose of the antitussive compound in the expectorant test were explored. Cross-validation was conducted based on the effective dose of the cough suppressant compound in the antitussive test and the effective dose of the cough suppressant compound in the expectorant test to determine the effective range of the effective dose of the cough suppressant compound under the dual antitussive and expectorant tests.

[0007] Optionally, the ammonia-induced cough model in young mice is configured with 5-8 test arrays, and the method for intervening in the ammonia-induced cough model in young mice specifically includes: Pure water was sent as the first drug sequence to the ammonia-induced cough model in young mice to intervene in the diseased test individuals in the first test array, and the first negative test data was obtained. Codeine phosphate tablets were sent as the second drug sequence to the ammonia-induced cough model in young mice to intervene in the diseased test individuals in the second test array, and the first positive test data was obtained. The lung-strengthening cough compound was sent as the third drug sequence to the ammonia-induced young mouse cough model to intervene in the diseased test individuals in the third test array, and the first commercially available control data was obtained. The cough-relieving compound was sent as the fourth drug sequence to the ammonia-induced cough model in young mice to intervene in the remaining test individuals in the test array; wherein different doses of the cough-relieving compound were loaded into each test array to obtain at least two sets of first dose comparison data. The ammonia-induced cough model in young mice sends the first negative test data, the first positive test data, the first commercially available control data, and several sets of first dose comparison data to the test result analysis sub-model to generate a first dose-response relationship curve to comprehensively evaluate the drug efficacy of the antitussive compound in inhibiting the frequency of cough induced by ammonia in young mice.

[0008] Optionally, the citrate-induced cough model in young guinea pigs generates 4-6 test arrays, and the method for intervening in the citrate-induced cough model in young guinea pigs specifically includes: Pure water was sent as the first drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the first test array, and second negative test data were obtained. Codeine phosphate tablets were sent as the second drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the second test array, thereby obtaining the second positive test data. The lung-strengthening cough compound was sent as the third drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the third test array, thus obtaining the second commercially available control data. The cough-relieving compound was sent as the fourth drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the remaining test individuals in the test array, thereby obtaining second dose comparison data; wherein the second dose comparison data was obtained based on the same or different doses of the cough-relieving compound to intervene in the test individuals in the test array. The citrate-induced cough model in young guinea pigs sends the second negative test data, the second positive test data, the second commercially available control data, and several sets of second dose comparison data to the test result analysis sub-model to generate a second dose-response curve to comprehensively evaluate the drug efficacy of the antitussive compound in inhibiting the frequency of citrate-induced cough in young guinea pigs.

[0009] Optionally, the rabbit isolated tracheal ciliary mucus movement model generates 4-6 test arrays, and the method for intervening in the rabbit isolated tracheal ciliary mucus movement model specifically includes: The tabletop liquid was sent as the first drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the diseased test individuals in the first test array, and the third negative test data was obtained. Epinephrine hydrochloride was sent as the second drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the diseased test individuals in the second test array, and the third positive test data was obtained. The lung-strengthening cough compound was sent as the third drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the diseased test individuals in the third test array, and the third commercially available control data was obtained. The cough-relieving compound was sent as the fourth drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the diseased test individuals in the remaining test array, and the third dose comparison data was obtained; wherein the third dose comparison data was obtained based on the same or different doses of the cough-relieving compound to intervene in the diseased test individuals in the test array. The rabbit isolated tracheal ciliary mucus motility model sends the third negative test data, the third positive test data, the third commercially available control data, and several sets of third dose comparison data to the test result analysis sub-model to generate a third dose-response relationship curve to comprehensively evaluate the drug efficacy of the antitussive compound in affecting the mucus motility activity of rabbit isolated tracheal ciliaries.

[0010] Optionally, the tracheal phenol red excretion model of young mice generates 4-6 test arrays, and the method for intervening in the tracheal phenol red excretion model of young mice specifically includes: Pure water was sent as the first drug sequence to the tracheal phenol red excretion model of the young mouse to intervene in the diseased test individuals in the first test array, and the fourth negative test data was obtained. Carbocysteine ​​tablets were sent as the second drug sequence to the tracheal phenol red excretion model of the young mouse to intervene in the diseased test individuals in the second test array, and the fourth positive test data was obtained. The lung-strengthening cough compound was sent as the third drug sequence to the tracheal phenol red excretion model of the young mouse to intervene in the diseased test individuals in the third test array, and the fourth commercially available control data was obtained. The cough-relieving compound was sent as the fourth drug sequence to the tracheal phenol red excretion model of the young mouse to intervene in the diseased test individuals in the remaining test array, and the fourth dose comparison data was obtained; wherein the fourth dose comparison data was obtained based on the same or different doses of the cough-relieving compound to intervene in the diseased test individuals in the test array. The tracheal phenol red excretion model in young mice sends the fourth negative test data, the fourth positive test data, the fourth commercially available control data, and several sets of fourth dose comparison data to the test result analysis sub-model to generate a fourth dose-response relationship curve to comprehensively evaluate the drug efficacy of the antitussive compound in affecting the tracheal phenol red excretion in young mice.

[0011] Optionally, the physiological indicator change data includes one or more of the following: cough frequency, cough latency, inflammatory factor levels, and immune cell activity data.

[0012] Optionally, the test result analysis sub-model preprocesses the physiological index change data of any individual in the drug efficacy test sub-model after drug administration to a standard form according to a set format; and performs inter-group variance analysis before comparing the test results of any two or more test arrays in the drug efficacy test sub-model. When the variances between groups are homogeneous, the test result analysis sub-model uses the Student-T test method to perform inter-group statistical analysis on the test results of any two or more test arrays in the same pharmacodynamic test sub-model. When the variances between groups are unequal, the test result analysis sub-model uses the corrected Student-T test method to perform inter-group statistical analysis on the test results of any two or more test arrays in the same pharmacodynamic test sub-model.

[0013] The beneficial effects that this invention can produce include: 1. The pharmacodynamic testing method for the cough-relieving compound provided by this invention integrates ammonia-induced cough model in young mice, citrate-induced cough model in young guinea pigs, rabbit isolated tracheal ciliary mucus movement model, and young mouse tracheal phenol red excretion model to construct an organismal model containing four core pharmacodynamic test sub-models. Each pharmacodynamic test sub-model sets up multiple test arrays and test individuals, forming a parallel validation system for antitussive and expectorant tests. Specifically, the antitussive onset dose of the cough-relieving compound is cross-validated using the ammonia-induced cough model in young mice and the citrate-induced cough model in young guinea pigs, and the effective expectorant dose is determined by combining the rabbit isolated tracheal ciliary mucus movement model and the young mouse tracheal phenol red excretion model. Finally, through cross-analysis of multiple dose-response curves, the effective dose range of the drug under the dual effects of antitussive and expectorant is clarified, solving the problem of the one-sidedness of traditional single-model evaluation and providing an important guarantee for the accuracy of drug efficacy determination.

[0014] 2. This invention sets up gradient dose interventions in each pharmacodynamic test sub-model and generates high-precision dose-response curves by comparing them with negative, positive, and commercially available control data. Taking an ammonia-induced cough model in young mice as an example, eight test arrays were constructed using pure water, codeine phosphate, a cough suppressant mixture, and five groups of different doses of the cough suppressant mixture. These arrays cover the ineffective dose, effective dose, and saturation dose ranges, accurately fitting the dose-response relationship of drug-induced cough suppression frequency. This avoids the curve distortion problem caused by insufficient dose gradient coverage in traditional experiments, providing a more reliable experimental basis for optimizing clinical drug dosage.

[0015] 3. This invention comprehensively determines drug efficacy by analyzing changes in multiple physiological indicators such as cough frequency, cough latency, ciliary movement speed, and phenol red excretion, ensuring the reliability of efficacy parameter evaluation. Furthermore, it preprocesses and statistically validates data through a test result analysis sub-model: converting the multi-dimensional physiological indicator changes into a standardized format to eliminate dimensional differences between different models; and performing a homogeneity of variance test before comparing multiple test arrays to avoid biased conclusions caused by inappropriate selection of statistical methods in traditional methods.

[0016] 4. This invention automates the configuration of pathogen data, drug sequence retrieval, and experimental cycle control using an organism model, achieving full-process standardization from loading the simulated experimental scenario to generating the pharmacodynamic evaluation report, thus reducing human error. Simultaneously, the analysis process rigorously defines the onset dose exploration logic and cross-validation rules for antitussive and expectorant trials, forming a reusable methodological architecture. This significantly improves the efficiency and reproducibility of pharmacodynamic trials for similar drugs, providing scientific and reliable technical support for drug development and clinical application. Attached Figure Description

[0017] Figure 1 This is a schematic diagram of the phenol red concentration standard curve in the pharmacodynamic test method of the cough-relieving compound of the present invention. Detailed Implementation

[0018] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0019] This invention provides a method for pharmacodynamic testing of a cough-relieving compound, comprising the following steps: selecting appropriate organism data to construct an organism model according to testing requirements; the organism model is configured with several pharmacodynamic testing sub-models and a test result analysis sub-model associated with all pharmacodynamic testing sub-models, each pharmacodynamic testing sub-model having at least two test arrays based on the same organism data; importing pathogen data into the organism model, configuring a corresponding number of pharmacodynamic testing sub-models according to the input category of the pathogen data, and configuring a corresponding number of test individuals in each test array based on the number of pathogen data to be tested in the pharmacodynamic testing sub-models, while simultaneously distributing the pathogen data one-to-one to multiple test individuals in each test array. The body data fusion process simulates the disease in each experimental individual to load a simulated experimental scenario. In the simulated scenario, the body model is automatically triggered to retrieve the corresponding drug sequence from its built-in drug configuration database according to the input category of the pathogen data, and sends it to the corresponding pharmacodynamic test sub-model for intervention within the set experimental period, obtaining physiological index change data for each experimental individual after drug administration. The physiological index change data of all experimental individuals after drug administration are sent to the test result analysis sub-model to evaluate the multi-dimensional pharmacodynamic parameters of the cough-relieving compound according to the set analysis process, and comprehensively determine the drug effectiveness based on the multi-dimensional pharmacodynamic parameters of the cough-relieving compound, while generating dose-response curves and outputting a pharmacodynamic evaluation report.

[0020] Furthermore, the pharmacodynamic test sub-models are any one of the following: ammonia-induced cough model in young mice, citrate-induced cough model in young guinea pigs, rabbit isolated tracheal ciliary mucus movement model, and young mouse tracheal phenol red excretion model. In the above, the analytical procedure is set as follows: Based on the ammonia-induced cough model in young mice and / or the citrate-induced cough model in young guinea pigs, the effective dose of the antitussive compound in the antitussive test is explored; based on the rabbit isolated tracheal ciliary mucus movement model and / or the young mouse tracheal phenol red excretion model, the effective dose of the antitussive compound in the expectorant test is explored; cross-validation is performed based on the effective doses of the antitussive compound in the antitussive test and the expectorant test to determine the effective range of the antitussive compound's dose in both antitussive and expectorant tests.

[0021] Furthermore, the ammonia-induced cough model in young mice was set up with 5-8 test arrays. The intervention methods for the ammonia-induced cough model specifically included: sending pure water as the first drug sequence to the ammonia-induced cough model in young mice to intervene in the diseased individuals in the first test array, obtaining the first negative test data; sending codeine phosphate tablets as the second drug sequence to the ammonia-induced cough model in young mice to intervene in the diseased individuals in the second test array, obtaining the first positive test data; and sending a lung-strengthening cough compound as the third drug sequence to the ammonia-induced cough model in young mice to intervene in the diseased individuals in the third test array. Intervention treatment was performed on the test individuals to obtain the first commercially available control data; the cough suppressant compound was sent as the fourth drug sequence to the ammonia-induced cough model for the remaining test individuals in the test array to intervene; different doses of the cough suppressant compound were loaded into each test array to obtain at least two sets of first dose comparison data; the ammonia-induced cough model for young mice sent the first negative test data, the first positive test data, the first commercially available control data, and several sets of first dose comparison data to the test result analysis sub-model to generate the first dose-response relationship curve to comprehensively evaluate the drug efficacy of the cough suppressant compound in inhibiting the frequency of cough in ammonia-induced cough in young mice.

[0022] Furthermore, a citrate-induced cough model in young guinea pigs was developed, generating 4-6 test arrays. The method for intervening in this model specifically included: sending pure water as the first drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the first test array, obtaining a second negative test data; sending codeine phosphate tablets as the second drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the second test array, obtaining a second positive test data; and sending a cough suppressant compound as the third drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the third test array. The process yielded a second set of commercially available control data. The cough suppressant compound was then sent as the fourth drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the remaining test individuals in the test array, resulting in a second dose comparison data. This second dose comparison data was obtained by intervening in test individuals in the test array with the same or different doses of the cough suppressant compound. The citrate-induced cough model in young guinea pigs sent the second negative test data, the second positive test data, the second commercially available control data, and several sets of second dose comparison data to the test result analysis sub-model to generate a second dose-response curve to comprehensively evaluate the drug efficacy of the cough suppressant compound in inhibiting the frequency of citrate-induced cough in young guinea pigs.

[0023] Furthermore, the rabbit isolated tracheal ciliary mucus movement model generates 4-6 test arrays, and the method for intervening in the rabbit isolated tracheal ciliary mucus movement model specifically includes: sending a drug solution as the first drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the experimental individuals with disease in the first test array, obtaining a third negative test data; sending adrenaline hydrochloride as the second drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the experimental individuals with disease in the second test array, obtaining a third positive test data; and sending a cough suppressant as the third drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the experimental individuals with disease in the third test array. Intervention treatment yielded the third commercially available control data. The cough-relieving compound was then sent as the fourth drug sequence to the rabbit isolated tracheal ciliary mucus motility model to intervene in the remaining test individuals in the test array, yielding the third dose comparison data. This third dose comparison data was obtained by intervening in the test individuals in the test array with the same or different doses of the cough-relieving compound. The rabbit isolated tracheal ciliary mucus motility model sent the third negative test data, the third positive test data, the third commercially available control data, and several sets of third dose comparison data to the test result analysis sub-model to generate a third dose-response curve to comprehensively evaluate the drug efficacy of the cough-relieving compound in affecting the mucus motility activity of rabbit isolated tracheal ciliaries.

[0024] Furthermore, the tracheal phenol red excretion model in young mice generated 4-6 test arrays, and the method for intervening in the tracheal phenol red excretion model in young mice specifically included: sending pure water as the first drug sequence to the tracheal phenol red excretion model in young mice to intervene in the experimental individuals with disease in the first test array, obtaining a fourth negative test data; sending carbocysteine ​​tablets as the second drug sequence to the tracheal phenol red excretion model in young mice to intervene in the experimental individuals with disease in the second test array, obtaining a fourth positive test data; and sending a cough suppressant compound as the third drug sequence to the tracheal phenol red excretion model in young mice to intervene in the experimental individuals with disease in the third test array. The process yielded the fourth commercially available control data. The cough suppressant compound was then sent as the fourth drug sequence to the tracheal phenol red excretion model in young mice to intervene in the remaining test individuals in the test array, resulting in the fourth dose comparison data. This fourth dose comparison data was obtained by intervening in the test individuals in the test array with the same or different doses of the cough suppressant compound. The tracheal phenol red excretion model in young mice sent the fourth negative test data, the fourth positive test data, the fourth commercially available control data, and several sets of fourth dose comparison data to the test result analysis sub-model to generate a fourth dose-response curve to comprehensively evaluate the drug efficacy of the cough suppressant compound in affecting the tracheal phenol red excretion in young mice.

[0025] Furthermore, the physiological indicator changes data include one or more of the following: cough frequency, cough latency, inflammatory factor levels, and immune cell activity. By comprehensively assessing drug efficacy using multi-dimensional physiological indicator changes data, the reliability of efficacy parameter evaluation is ensured. Data preprocessing and statistical validation are performed through a test result analysis sub-model: the multi-dimensional physiological indicator changes data are uniformly converted into a standard format to eliminate dimensional differences between different models; and homogeneity of variance tests are performed before comparing multiple test arrays to avoid biases in conclusions caused by inappropriate selection of statistical methods in traditional approaches.

[0026] Specifically, the test results analysis sub-model preprocesses the physiological index changes of test individuals after drug administration from any of the pharmacodynamic test sub-models into a standard format, such as EXCEL, according to a set format. Before comparing the test results of any two or more test arrays in the pharmacodynamic test sub-model, it performs an analysis of variance between groups. When the variances between groups are homogeneous, the test results analysis sub-model uses the Student-T test to perform statistical analysis between groups of test results from any two or more test arrays in the same pharmacodynamic test sub-model. When the variances between groups are unequal, the test results analysis sub-model uses a corrected Student-T test to perform statistical analysis between groups of test results from any two or more test arrays in the same pharmacodynamic test sub-model.

[0027] Example 1 The experimental method for constructing a simulation scenario for an ammonia-induced cough model in young mice includes: S101, Configure machine data SPF-grade ICR juvenile mice, weighing 18-22g, were selected and observed for 7 days under the following environmental conditions: temperature 22-25℃, humidity 40%-60%, 12-hour light-dark cycle, and free access to food and water. After 7 days, individuals exhibiting lethargy or abnormal weight were excluded, resulting in 96 qualified mice. These 96 mice were then randomly and evenly distributed into 8 test arrays, with 12 mice in each group (6 males and 6 females). The mice were fasted for 12 hours prior to the experiment (water was allowed) to prevent food residue from interfering with the observation of the cough response.

[0028] S102, Model-Induced Construction Prepare a 25% ammonia solution by mixing pure ammonia and pure water at a volume ratio of 1:3. Use an ultrasonic nebulizer (nebulization rate 0.5 mL / min) to generate ammonia nebulized gas. Place mice individually in an inverted 500 mL sealed beaker, with the nebulizer outlet connected to the top of the beaker. Continuously introduce ammonia nebulized gas into the beaker for 5 seconds, then stop nebulization. Simultaneously start a stopwatch to record the number of coughs and cough latency of the mice within 2 minutes. A valid cough is defined as abdominal contraction, mouth opening, tongue lifting, and accompanied by a coughing sound. The cough latency is the time from the start of nebulization to the first cough. If the average number of coughs in the mice within 2 minutes is ≥30 and the cough latency is ≤30 seconds, the ammonia-induced cough model in young mice is considered successfully induced, and a simulated experimental scenario is generated.

[0029] S103, Intervention Treatment First test array (negative control group): Pure water was administered at a volume of 10 mL / kg, once daily for 7 consecutive days; The second test array (positive control group): codeine phosphate tablets (dose 8.78 mg / kg, concentration 0.878 mg / mL) were administered only once (pure water was given for the first 6 days), with a dosing volume of 10 mL / kg; The third test array (commercially available control group): Pulmonary cough syrup (dosage 1.2g crude drug / kg, concentration 0.12g crude drug / mL) was administered once daily for 7 consecutive days, with a dosing volume of 10mL / kg; The fourth to eighth test arrays (cough-relieving compound dosage groups): Cough-relieving compound was administered at doses of 0.49 g crude drug / kg (concentration 0.049 g crude drug / mL), 0.97 g crude drug / kg (concentration 0.097 g crude drug / mL), 1.94 g crude drug / kg (concentration 0.194 g crude drug / mL), 3.88 g crude drug / kg (concentration 0.388 g crude drug / mL), and 7.76 g crude drug / kg (concentration 0.776 g crude drug / mL), once daily for 7 consecutive days, with a dosage volume of 10 mL / kg.

[0030] S104. Model Validation and Indicator Collection and Analysis One hour after the last administration or 30 minutes after administration to the positive control group, the ammonia nebulization induction procedure in step S102 was repeated, and the number of coughs and latency period within 2 minutes were recorded for each group. If the number of coughs in the positive control group was significantly reduced compared to the negative control group (P<0.05), and the number of coughs in the high-dose group of the cough suppressant mixture (dose of 1.94 g crude drug / kg and above) showed a dose-dependent reduction, the ammonia-induced cough model in young mice was deemed effective and could be used for evaluating the effective dose of the cough suppressant mixture. The experimental results are shown in Table 1. Table 1. Effects of antitussive compound on ammonia-induced cough model in young mice.

[0031] Where n is the number of individuals tested; compared with the negative control group: * This indicates that P < 0.05. ** This indicates that P < 0.01; P is a probability value used to measure the probability that the difference in efficacy between the two groups of drugs is caused by random error. The smaller the P value, the lower the possibility of random factors affecting the outcome.

[0032] As shown in Table 1, all animals in the negative control group developed significant coughing after inhaling ammonia, indicating that the cough model was successfully established. Compared with the negative control group, the positive control group showed a significant reduction in the number of coughs. This is because codeine phosphate selectively inhibits the cough center in the medulla oblongata, resulting in a strong and rapid antitussive effect. The cough latency was not significantly affected in the antitussive mixture groups I, II, III, IV, and V, but the number of coughs was significantly reduced in the antitussive mixture groups III, IV, and V, indicating that the antitussive mixture has a certain inhibitory effect on ammonia-induced cough in young mice, and exhibits a certain degree of dose-response relationship.

[0033] Example 2 The method for constructing a citrate-induced cough model in young guinea pigs includes: S201, Configure machine data SPF-grade Hartley juvenile guinea pigs, weighing 200-250g, were selected and observed for 7 days under the following environmental conditions: temperature 22-25℃, humidity 40%-60%, 12-hour light-dark cycle, and free access to food and water. The feed consisted of guinea pig-specific pelleted feed supplemented with Vitamin C. After 7 days, individuals exhibiting abnormal breathing or ruffled fur were culled. The culling method involved placing the guinea pigs in a 2L sealed beaker, introducing 17.5% citric acid atomized gas for 30 seconds, and recording the number of coughs within 5 minutes. Individuals coughing less than 10 times within 5 minutes were culled, resulting in 48 qualified guinea pigs. These 48 guinea pigs were then randomly and evenly distributed into 6 test groups, with 8 individuals in each group (4 males and 4 females).

[0034] S202, Model-Induced Construction Prepare a 17.5% citric acid solution: Dissolve citric acid powder in pure water and degas using ultrasound for 10 minutes; then use an ultrasonic nebulizer (nebulization rate of 1.0 mL / min) to generate citric acid atomized gas; place the guinea pigs individually in a 2L sealed beaker with a pre-reserved ventilation hole on the side wall of the beaker (e.g., 0.5 cm in diameter to avoid hypoxia), continuously circulate the citric acid atomized gas for 30 seconds and then stop, start a stopwatch, and record the number of coughs and latency within 5 minutes. A valid cough is defined as the guinea pig extending its neck, opening its mouth, and coughing clearly. If the negative control group has an average of ≥15 coughs and a latency of ≤120 seconds within 5 minutes, the citric acid-induced cough model in young guinea pigs is considered successfully induced, and a simulated experimental scenario is generated.

[0035] S203, Intervention Treatment First test array (negative control group): Pure water was administered at a volume of 10 mL / kg, once daily for 7 consecutive days; The second test array (positive control group): codeine phosphate tablets (dose 6.44 mg / kg, concentration 0.644 mg / mL) were administered, with only one dose at the last administration, and the administration volume was 10 mL / kg; The third test array (commercially available control group): Pulmonary cough syrup (dosage 1.8g crude drug / kg, concentration 0.18g crude drug / mL) was administered once daily for 7 consecutive days, with a dosing volume of 10mL / kg; The fourth to sixth test arrays (cough-relieving compound dosage groups): cough-relieving compound was administered at doses of 0.71 g crude drug / kg (concentration 0.071 g crude drug / mL), 1.42 g crude drug / kg (concentration 0.142 g crude drug / mL), and 2.84 g crude drug / kg (concentration 0.284 g crude drug / mL), respectively, once daily for 7 consecutive days, with a dosage volume of 10 mL / kg.

[0036] S204. Model Validation and Indicator Collection and Analysis One hour after the last administration or 30 minutes after administration to the positive control group, the citrate nebulization induction procedure in step S202 was repeated, and the number of coughs and latency period within 5 minutes were recorded for each group of guinea pigs. If the number of coughs in the positive control group was significantly reduced compared to the negative control group (P<0.05), and the number of coughs in the high-dose group of the antitussive compound (dose of 1.42 g crude drug / kg and above) showed a dose-dependent reduction, the citrate-induced cough model in young guinea pigs was deemed effective and could be used for the evaluation and analysis of the effective dose of the antitussive compound. The experimental results are shown in Table 2. Table 2. Effects of the antitussive compound on a citrate-induced cough model in young guinea pigs.

[0037] Where n is the number of individuals tested; compared with the negative control group: * This indicates that P < 0.05. ** This indicates that P < 0.01.

[0038] As shown in Table 2, all animals in the negative control group developed significant coughing after inhaling citric acid, indicating that the cough model was successfully established. Compared with the negative control group, the positive control group showed a significant reduction in the number of coughs. This is because codeine phosphate selectively inhibits the cough center in the medulla oblongata, resulting in a strong and rapid antitussive effect. The low, medium, and high doses of the antitussive compound did not significantly affect the cough latency period, but the medium and high doses significantly reduced the number of coughs, indicating that the antitussive compound has a certain inhibitory effect on citric acid-induced cough in young guinea pigs, and exhibits a certain degree of dose-response relationship.

[0039] Example 3 The experimental method for constructing a simulation test scenario for an isolated rabbit tracheal ciliary mucus movement model includes: S301, Configure machine data Twenty-two SPF-grade young New Zealand rabbits, weighing between 1.5 and 2.0 kg, were selected and observed for 3 days under the following environmental conditions: temperature 20-24℃, humidity 50%-60%, with free access to food and water. Two tracheal specimens were prepared from each rabbit, resulting in a final selection of 36 specimens. These specimens were then divided into 6 test arrays, with 6 individuals in each array, based on the principle of balanced tracheal ciliary movement rate. The principle of balanced tracheal ciliary movement rate involved pre-testing the ink flow rate of each specimen to ensure no difference between groups.

[0040] S302, Model-Induced Construction Prepare a Tyrode solution preheated to 37℃ in advance. The raw material components are as follows by mass ratio: NaCl 8.0g, KCl 0.2g, CaCl2 0.2g, MgSO4 0.1g, NaHCO3 1.0g, NaH2PO4 0.05g, and glucose 1.0g. Dilute with pure water to 1000mL, adjust the pH to 7.3-7.4, and saturate with a mixture of 95% O2 and 5% CO2 for 30 minutes to obtain a 37℃ saturated oxygen Tyrode solution for later use.

[0041] Place the rabbit in a sealed container and introduce an excessive amount of CO2 until the rabbit loses its spontaneous breathing and becomes comatose. Immediately euthanize the rabbit by injecting 10 mL of air into the ear vein. Quickly cut open the skin on the neck and separate the trachea, from the larynx to the bifurcation of the trachea, avoiding damage to the tracheal mucosa. Then immediately place the separated trachea into a 37°C saturated oxygen Tyrode solution and gently rinse it twice to remove blood. Cut the trachea into 1.0-1.5cm segments, cut them longitudinally, keeping the tracheal lining intact and facing upwards, to obtain two specimens. Place the specimens in a petri dish lined with cotton moistened with Tyrode's solution at 37°C, with a constant temperature pad placed under the cotton to maintain 37°C, keeping the trachea tilted at 30° with the larynx facing upwards, thus completing the construction of the rabbit isolated tracheal ciliary mucus movement model.

[0042] S303, Intervention Treatment First test array (negative control group): The specimen was incubated in 37°C saturated oxygen Tyrode solution for 5 minutes; Second test array (positive control group): The specimen was placed in a 2.0×10⁻⁶ m² / g² test array. -5 Incubate g / mL epinephrine hydrochloride in 37°C saturated oxygen Tyrode's solution for 5 minutes; The third test array (commercially available control group): The specimens were incubated in Tyrode's solution at 37°C with 0.088 g crude drug / mL of Pulmonary Cough Mixture for 5 minutes; The fourth to sixth test arrays (cough-relieving compound dosage groups): The specimens were placed in 37°C saturated oxygen Tyrode solution containing 0.034 g crude drug / mL, 0.068 g crude drug / mL, and 0.136 g crude drug / mL cough-relieving compound, respectively, and incubated for 5 minutes.

[0043] S304. Model Validation and Indicator Collection After incubation, 1 μL of Indian ink was aspirated using a microsyringe and dropped onto the inner membrane of the lower trachea. The time it took for the ink particles to travel 2 mm was observed using a dissecting microscope. Each specimen was observed twice, and the average value was taken. The ciliary movement rate was calculated in mm / min. Cilia travel rate = 2 / t × 60; Where t is the average time for the ink to travel 2 mm, in seconds; After intervention, all specimens were incubated again in 37℃ saturated oxygen Tyrode's solution for 5 minutes, and the above tests were repeated to verify the mucosal motility activity of isolated rabbit trachea cilia. If the ciliary motility rate decreased by ≤20% compared with before intervention during activity verification, the specimen activity was considered normal. Simultaneously, if the ciliary motility rate in the positive control group was significantly increased compared with the negative control group (P<0.05), the model construction was considered effective, and the motility activity of isolated rabbit trachea cilia could be used to assess the effective dose of the antitussive compound. The experimental results are shown in Table 3. Table 3. Effects of the cough-relieving compound on the ciliary movement of isolated rabbit trachea.

[0044] Where n is the number of individuals tested; compared with the negative control group: * This indicates that P < 0.05. ** This indicates that P < 0.01.

[0045] As shown in Table 3, before drug administration, the transit time and rate of ciliary mucus in isolated trachea were similar across all experimental groups, indicating a balanced grouping. The tracheal activity verification results during and after the experiment demonstrated that isolated trachea in all experimental groups remained active throughout the entire experiment, proving the stability of the experimental system. After drug administration, the transit time and rate of ciliary mucus in the isolated trachea of ​​the positive control group significantly decreased, which is related to the positive drug (epinephrine hydrochloride) acting on bronchial smooth muscle β2 receptors, causing bronchial smooth muscle dilation, reducing microvascular permeability, and increasing tracheal epithelial cilia movement. After drug administration, the transit rate of ciliary mucus in isolated trachea also significantly increased in the commercially available control group and the high-dose cough suppressant mixture group, indicating that both the commercially available control drug (lung-strengthening cough suppressant mixture) and the cough suppressant mixture have certain expectorant effects, but no significant difference was observed in their expectorant efficacy.

[0046] Example 4 The experimental method for constructing a simulation scenario for the tracheal phenol red excretion model in young mice specifically includes: S401, Configure machine data SPF-grade ICR juvenile mice, weighing 18-22g, were selected and observed for 7 days under the following environmental conditions: temperature 22-25℃, humidity 40%-60%, 12-hour light-dark cycle, and free access to food and water. Individuals with abnormal weight were removed, and 72 qualified mice were finally selected. These 72 qualified mice were then randomly and evenly distributed into 6 test arrays; each test array contained 12 test individuals (qualified mice), with 6 males and 6 females.

[0047] S402, Collaborative Construction of Model Induction and Intervention First test array (negative control group): Pure water was administered at a volume of 10 mL / kg, once daily for 7 consecutive days; The second test array (positive control group): Carbocysteine ​​tablets 0.22 g / kg were administered, with only one dose given at the last administration (pure water was given for the first 6 days), and the administration volume was 10 mL / kg; The third test array (commercially available control group): Pulmonary cough syrup (dosage 1.2g crude drug / kg, concentration 0.12g crude drug / mL) was administered once daily for 7 consecutive days, with a dosing volume of 10mL / kg; The fourth to sixth test arrays (cough-relieving compound dosage groups): cough-relieving compound was administered at doses of 0.97 g crude drug / kg (concentration of 0.097 g crude drug / mL), 1.94 g crude drug / kg (concentration of 0.194 g crude drug / mL), and 3.88 g crude drug / kg (concentration of 0.388 g crude drug / mL), respectively, once daily for 7 consecutive days; Thirty minutes after the last administration, all mice were injected intraperitoneally with 5% phenol red solution (dose 10 mL / kg). Thirty minutes after the injection, the mice were sacrificed using the "CO2 coma + air embolism" method to complete the model induction. Phenol red was secreted and accumulated in the tracheal mucosa.

[0048] S403. Specimen Processing and Index Collection and Analysis Prepare a 5% phenol red solution in advance: Dissolve phenol red powder in physiological saline, filter to remove bacteria, and dilute with 5% sodium bicarbonate solution to obtain 2.5 mL of 5% sodium bicarbonate solution for later use; After euthanizing the mouse, quickly cut open the skin on the neck and separate the trachea from the cricoid cartilage to the bifurcation of the trachea, avoiding bleeding and contamination; place the trachea into a centrifuge tube containing 2.5 mL of 5% sodium bicarbonate solution and sonicate at 200 W and 40 kHz for 30 minutes to fully dissolve the phenol red in the trachea. After sonication, let the centrifuge tube stand for 5 minutes, collect the supernatant, and measure the OD value (absorbance, an indicator used to measure the degree to which a solution absorbs light at a specific wavelength) at a wavelength of 546 nm using a UV spectrophotometer. Combine this with the phenol red standard curve as shown below. Figure 1 As shown, the phenol red content in the supernatant was calculated. The method for plotting the phenol red standard curve was as follows: Phenol red was quantitatively weighed using a balance, dissolved in 5% sodium bicarbonate solution to prepare a solution with a phenol red content of 100 μg / mL, and then sequentially diluted to solutions containing 0.1 μg, 0.3 μg, 0.5 μg, 0.75 μg, 1.0 μg, 3.0 μg, 5.0 μg, and 10.0 μg of phenol red per milliliter. The OD values ​​were measured sequentially. Then, a linear regression equation was fitted with phenol red concentration as the abscissa and OD value as the ordinate to generate the phenol red standard curve.

[0049] If the phenol red content in the positive control group was significantly higher than that in the negative control group (P<0.01), and the phenol red content in each dose group of the cough suppressant compound increased in a dose-dependent manner, then the tracheal phenol red excretion model in young mice was deemed effective. The amount of phenol red excreted from the trachea of ​​young mice could be used to assess the effective dose of the cough suppressant compound for expectorant efficacy. The experimental results are shown in Table 4. Table 4. Effects of antitussive compound on tracheal phenol red excretion in young mice.

[0050] Where n is the number of individuals tested; compared with the negative control group: * This indicates that P < 0.05. ** This indicates P < 0.01; compared with the commercially available control group: # This indicates that P < 0.05. ## This indicates that P < 0.01.

[0051] As shown in Table 4, compared with the negative control group, the phenol red content in the positive control group, the commercially available control group, and the low, medium, and high dose groups of the cough suppressant mixture was significantly increased, indicating that the positive control, the commercially available control, and the cough suppressant mixture could all promote the excretion of phenol red from the trachea of ​​young mice. Compared with the commercially available control group, the phenol red content in the medium and high dose groups of the cough suppressant mixture was significantly increased, indicating that the medium and high dose groups of the cough suppressant mixture had a better effect on the excretion of phenol red from the trachea of ​​young mice than the commercially available control group.

[0052] In summary, the pharmacodynamic testing method of the cough suppressant provided by this invention, cross-validated by the test results in Tables 1-4, shows that in the antitussive study: in the ammonia-induced cough model in young mice, the cough suppressant can inhibit the number of coughs in young mice, with an effective dose of 1.94 g crude drug / kg, and a certain dose-response relationship is observed. In the citrate-induced cough model in young guinea pigs, the cough suppressant can also inhibit the number of coughs in young guinea pigs, with an effective dose of 1.42 g crude drug / kg, also showing a certain dose-response relationship. Regarding the inhibitory effect on the above two young animal cough models, there is no significant difference between the cough suppressant and the commercially available control group (lung-strengthening cough suppressant). In expectorant studies: In a rabbit isolated tracheal ciliary movement model, the antitussive compound at a concentration of 0.136 g crude drug / mL accelerated the mucus movement of isolated rabbit tracheal cilia, indicating that the antitussive compound has a certain expectorant effect. Compared with the lung-strengthening cough compound at a dose of 0.088 g raw drug / mL, the antitussive compound showed no significant difference in its effect on the movement of isolated rabbit tracheal cilia at doses of 0.034 g crude drug / mL, 0.068 g crude drug / mL, and 0.136 g crude drug / mL. In a tracheal phenol red excretion model in young mice, the antitussive compound promoted the excretion of phenol red from the trachea of ​​young mice, with an effective dose of 0.97 g crude drug / kg, showing a certain degree of dose-response relationship. The antitussive compound at doses of 1.94 g crude drug / kg and 3.88 g crude drug / kg was significantly better than the lung-strengthening cough compound (1.2 g crude drug / kg) in promoting the excretion of phenol red from the trachea of ​​young mice.

Claims

1. A pharmacodynamic testing method for a cough-relieving compound, characterized in that, Includes the following steps: According to the testing requirements, the corresponding organism data is selected to construct the organism model; the organism model is set with several drug efficacy test sub-models and test result analysis sub-models that are associated with all the drug efficacy test sub-models, and each drug efficacy test sub-model is set with at least two test arrays based on the same organism data; Pathogen data is imported into the organism model. The organism model is configured with a corresponding number of drug efficacy test sub-models according to the input category of the pathogen data. In the drug efficacy test sub-model, a corresponding number of test individuals are configured in each test array based on the number of pathogen data to be tested. At the same time, the pathogen data is distributed one-to-one to be fused with the data of multiple test individuals in each test array, so that each test individual becomes ill to load the simulated test scenario. In the simulated test scenario, the organism model is automatically triggered to retrieve the corresponding drug sequence from its built-in drug configuration database according to the input category of the pathogen data, and send it to the corresponding drug efficacy test sub-model for intervention within the set test period to obtain physiological indicator change data of each test individual after drug administration; The physiological index changes of all the test individuals after administration are sent to the test result analysis sub-model. The multi-dimensional efficacy parameters of the cough-relieving compound are evaluated according to the set analysis process. The efficacy of the drug is determined based on the multi-dimensional efficacy parameters of the cough-relieving compound. At the same time, a dose-response curve is generated and a pharmacodynamic evaluation report is output.

2. The pharmacodynamic testing method for the cough-relieving compound according to claim 1, characterized in that, The pharmacodynamic test sub-model is any one of the following: ammonia-induced cough model in young mice, citric acid-induced cough model in young guinea pigs, rabbit isolated tracheal ciliary mucus movement model, and young mouse tracheal phenol red excretion model.

3. The pharmacodynamic testing method for the cough-relieving compound according to claim 2, characterized in that, The analysis process is set as follows: Based on the ammonia-induced cough model in young mice and / or the citrate-induced cough model in young guinea pigs, the effective dose of the antitussive compound in the antitussive test was explored. Based on the rabbit isolated tracheal ciliary mucus movement model and / or the tracheal phenol red excretion model of young mice, the efficacy and effective dose of the antitussive compound in the expectorant test were explored. Cross-validation was conducted based on the effective dose of the cough suppressant compound in the antitussive test and the effective dose of the cough suppressant compound in the expectorant test to determine the effective range of the effective dose of the cough suppressant compound under the dual antitussive and expectorant tests.

4. The pharmacodynamic testing method for the cough-relieving compound according to claim 2, characterized in that, The ammonia-induced cough model in young mice is configured with 5-8 test arrays, and the method for intervening in the ammonia-induced cough model in young mice specifically includes: Pure water was sent as the first drug sequence to the ammonia-induced cough model in young mice to intervene in the diseased test individuals in the first test array, and the first negative test data was obtained. Codeine phosphate tablets were sent as the second drug sequence to the ammonia-induced cough model in young mice to intervene in the diseased test individuals in the second test array, and the first positive test data was obtained. The lung-strengthening cough compound was sent as the third drug sequence to the ammonia-induced young mouse cough model to intervene in the diseased test individuals in the third test array, and the first commercially available control data was obtained. The cough-relieving compound was sent as the fourth drug sequence to the ammonia-induced cough model in young mice to intervene in the remaining test individuals in the test array; wherein different doses of the cough-relieving compound were loaded into each test array to obtain at least two sets of first dose comparison data. The ammonia-induced cough model in young mice sends the first negative test data, the first positive test data, the first commercially available control data, and several sets of first dose comparison data to the test result analysis sub-model to generate a first dose-response relationship curve to comprehensively evaluate the drug efficacy of the antitussive compound in inhibiting the frequency of cough induced by ammonia in young mice.

5. The pharmacodynamic testing method for the cough-relieving compound according to claim 2, characterized in that, The method for generating 4-6 test arrays for the citrate-induced cough model in young guinea pigs, and the method for intervening in the citrate-induced cough model in young guinea pigs, specifically includes: Pure water was sent as the first drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the first test array, and second negative test data were obtained. Codeine phosphate tablets were sent as the second drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the second test array, thereby obtaining the second positive test data. The lung-strengthening cough compound was sent as the third drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the diseased individuals in the third test array, thus obtaining the second commercially available control data. The cough-relieving compound was sent as the fourth drug sequence to the citrate-induced cough model in young guinea pigs to intervene in the remaining test individuals in the test array, thereby obtaining second dose comparison data; wherein the second dose comparison data was obtained based on the same or different doses of the cough-relieving compound to intervene in the test individuals in the test array. The citrate-induced cough model in young guinea pigs sends the second negative test data, the second positive test data, the second commercially available control data, and several sets of second dose comparison data to the test result analysis sub-model to generate a second dose-response curve to comprehensively evaluate the drug efficacy of the antitussive compound in inhibiting the frequency of citrate-induced cough in young guinea pigs.

6. The pharmacodynamic testing method for the cough-relieving compound according to claim 2, characterized in that, The rabbit isolated tracheal ciliary mucus movement model generates 4-6 test arrays, and the method for intervening in the rabbit isolated tracheal ciliary mucus movement model specifically includes: The tabletop liquid was sent as the first drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the diseased test individuals in the first test array, and the third negative test data was obtained. Epinephrine hydrochloride was sent as the second drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the diseased test individuals in the second test array, and the third positive test data was obtained. The lung-strengthening cough compound was sent as the third drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the diseased test individuals in the third test array, and the third commercially available control data was obtained. The cough-relieving compound was sent as the fourth drug sequence to the rabbit isolated tracheal ciliary mucus movement model to intervene in the diseased test individuals in the remaining test array, and the third dose comparison data was obtained; wherein the third dose comparison data was obtained based on the same or different doses of the cough-relieving compound to intervene in the diseased test individuals in the test array. The rabbit isolated tracheal ciliary mucus motility model sends the third negative test data, the third positive test data, the third commercially available control data, and several sets of third dose comparison data to the test result analysis sub-model to generate a third dose-response relationship curve to comprehensively evaluate the drug efficacy of the antitussive compound in affecting the mucus motility activity of rabbit isolated tracheal ciliaries.

7. The pharmacodynamic testing method for the cough-relieving compound according to claim 2, characterized in that, The method for generating 4-6 test arrays in the tracheal phenol red excretion model of young mice and the method for intervening in the tracheal phenol red excretion model of young mice specifically includes: Pure water was sent as the first drug sequence to the tracheal phenol red excretion model of the young mouse to intervene in the diseased test individuals in the first test array, and the fourth negative test data was obtained. Carbocysteine ​​tablets were sent as the second drug sequence to the tracheal phenol red excretion model of the young mouse to intervene in the diseased test individuals in the second test array, and the fourth positive test data was obtained. The lung-strengthening cough compound was sent as the third drug sequence to the tracheal phenol red excretion model of the young mouse to intervene in the diseased test individuals in the third test array, and the fourth commercially available control data was obtained. The cough-relieving compound was sent as the fourth drug sequence to the tracheal phenol red excretion model of the young mouse to intervene in the diseased test individuals in the remaining test array, and the fourth dose comparison data was obtained; wherein the fourth dose comparison data was obtained based on the same or different doses of the cough-relieving compound to intervene in the diseased test individuals in the test array. The tracheal phenol red excretion model in young mice sends the fourth negative test data, the fourth positive test data, the fourth commercially available control data, and several sets of fourth dose comparison data to the test result analysis sub-model to generate a fourth dose-response relationship curve to comprehensively evaluate the drug efficacy of the antitussive compound in affecting the tracheal phenol red excretion in young mice.

8. The pharmacodynamic testing method for the cough-relieving compound according to claim 1, characterized in that, The physiological indicator data includes one or more of the following: cough frequency, cough latency, inflammatory factor levels, and immune cell activity.

9. The pharmacodynamic testing method for the cough-relieving compound according to claim 1, characterized in that, The test result analysis sub-model preprocesses the physiological index change data of any individual in the drug efficacy test sub-model after drug administration into a standard form according to a set format; and performs inter-group variance analysis before comparing the test results of any two or more test arrays in the drug efficacy test sub-model. When the variances between groups are homogeneous, the test result analysis sub-model uses the Student-T test method to perform inter-group statistical analysis on the test results of any two or more test arrays in the same pharmacodynamic test sub-model. When the variances between groups are unequal, the test result analysis sub-model uses the corrected Student-T test method to perform inter-group statistical analysis on the test results of any two or more test arrays in the same pharmacodynamic test sub-model.

Images